NASDAQ:MDWD

MediWound Stock Forecast, Price & News

$5.28
-0.11 (-2.04 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.21
Now: $5.28
$5.42
50-Day Range
$4.87
MA: $5.33
$5.77
52-Week Range
$1.61
Now: $5.28
$6.07
Volume36,349 shs
Average Volume160,051 shs
Market Capitalization$143.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound logo

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010
Employees75
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.79 million
Cash Flow$0.13 per share
Book Value$0.56 per share

Profitability

Net Income$4.95 million

Miscellaneous

Market Cap$143.81 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable

Headlines

MediWound (NASDAQ:MDWD) Shares Up 6.9%
March 17, 2021 |  americanbankingnews.com
Form 6-K MediWound Ltd. For: Feb 22 - StreetInsider.com
February 22, 2021 |  streetinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

710th out of 2,010 stocks

Medicinals & Botanicals Industry

3rd out of 33 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$5.28
-0.11 (-2.04 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound
or view top-rated stocks.

What stocks does MarketBeat like better than MediWound?

Wall Street analysts have given MediWound a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediWound wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MediWound?

MediWound saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 33,000 shares, an increase of 52.8% from the February 11th total of 21,600 shares. Based on an average daily trading volume, of 154,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the stock are short sold.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for MediWound
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. The biopharmaceutical company had revenue of $6.67 million for the quarter, compared to the consensus estimate of $5.59 million. MediWound had a negative net margin of 53.12% and a negative trailing twelve-month return on equity of 94.63%.
View MediWound's earnings history
.

How has MediWound's stock been impacted by Coronavirus?

MediWound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDWD stock has increased by 128.6% and is now trading at $5.28.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MDWD?

4 equities research analysts have issued twelve-month target prices for MediWound's shares. Their forecasts range from $6.00 to $10.00. On average, they expect MediWound's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price.
View analysts' price targets for MediWound
or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?

MediWound's management team includes the following people:
  • Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 49, Pay $520k)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 75, Pay $440k)
  • Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 47, Pay $341k)
  • Mr. Yaron Meyer, Exec. VP, Gen. Counsel & Corp. Sec. (Age 42, Pay $315k)
  • Dr. Ety Klinger, Chief R&D Officer (Age 59, Pay $375k)
  • Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 64)

Who are some of MediWound's key competitors?

What other stocks do shareholders of MediWound own?

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $5.28.

How much money does MediWound make?

MediWound has a market capitalization of $143.81 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 75 workers across the globe.

What is MediWound's official website?

The official website for MediWound is www.mediwound.com.

Where are MediWound's headquarters?

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.